Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Lanax warning letter

This article was originally published in The Tan Sheet

Executive Summary

Lanax warning letter: Carma Labs receives notice from FDA that Lanax Ointment, a hemorrhoid treatment, fails to meet the requirements of the anorectal OTC monograph. Two ingredients, phenol and salicylic acid, are not considered safe and effective for treatment of hemorrhoids, FDA says. In addition, the product fails to bear appropriate warnings, directions and a statement of identity. Also, a January FDA inspection found "deviations" from the CGMP regs, including the failure of production and packaging records to show the amount of product packaged under the Lanex label...

Topics

UsernamePublicRestriction

Register

PS085885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel